What is PepGen's market cap?

PepGen (PEPG) has a market capitalization of $131.4M and trades on NASDAQ.

Who are PepGen's competitors?

PepGen's key competitors include Sarepta Therapeutics, Inc., Dyne Therapeutics, Entrada Therapeutics, Inc., and others. These companies compete in similar markets and product categories.

Who does PepGen partner with?

PepGen's notable partners include Oxford University Innovation Limited, Medical Research Council, Sarepta Therapeutics, Inc., and others.

Where is PepGen headquartered?

PepGen is headquartered in United States of America and employs approximately 65 people. It has been publicly traded since 2022.

PepGen

PEPG

PepGen Inc. is a clinical-stage biotechnology company developing the next generation of oligonucleotide therapeutics for severe neuromuscular and neurologic diseases.

Market cap

$131.42M+191%

Table of contents

Earnings

Q1 2026 report

May 12, 2026

EPS-$0.26Beat by $0.05

Read the full report

Next report

Aug 6, 2026 (In 1 week)

EPS estimate-$0.30

Competitors

By market cap

ALN

Alnylam Pharmaceuticals$37.2B-12.2%

Arrowhead Research$12.0B+439%

Ionis Pharmaceuticals$9.2B+41.1%

Dyne Therapeutics, Inc.$4.2B+222%

Sarepta Therapeutics, Inc.$1.7B+23.2%

Entrada Therapeutics$236.0M-0.2%

Atrium Therapeutics $197.9M-95.2%

PepGen$131.4M+181%

By revenue growth

ALN

Alnylam Pharmaceuticals+82.6%

Arrowhead Research+14.1%

Sarepta Therapeutics, Inc.+9.9%

Ionis Pharmaceuticals-7.4%

By net margin

ALN

Alnylam Pharmaceuticals11.72%+21.5pp

Sarepta Therapeutics, Inc.4.64%-38.4pp

Arrowhead Research-48.38%-22.0pp

Ionis Pharmaceuticals-64.7%-36.3pp

Profile

PepGen Inc. is a clinical-stage biotechnology company developing the next generation of oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. The company utilizes its proprietary Enhanced Delivery Oligonucleotide (EDO) platform, which leverages cell-penetrating peptides to improve the uptake and activity of conjugated therapeutics in target tissues like skeletal and cardiac muscle.

Competitive position

Clinical-stage innovator focused on overcoming the delivery challenges of oligonucleotide therapeutics through a proprietary peptide-conjugation platform.

GeographiesUnited States, Canada, United Kingdom, European Union, South Korea, Australia, New Zealand

Customer segmentsRare disease patients, Specialty healthcare providers

Business modelR&D intensive, IP licensing

SuppliersContract Development and Manufacturing Organizations (CDMOs), Academic research institutions, Raw material suppliers for peptides and oligonucleotides

CustomersSpecialty pharmacies, Hospitals, Clinical trial participants

CountryUnited States of America

Listed2022

Employees65.0

CEOJames McArthur

SectorHealthcare

IndustryBiotechnology

Websitepepgen.com

FilingsSEC EDGAR

Questions, answered.

What is PepGen's market cap?: PepGen (PEPG) has a market capitalization of $131.4M and trades on NASDAQ.
Who are PepGen's competitors?: PepGen's key competitors include Sarepta Therapeutics, Inc., Dyne Therapeutics, Entrada Therapeutics, Inc., and others. These companies compete in similar markets and product categories.
Who does PepGen partner with?: PepGen's notable partners include Oxford University Innovation Limited, Medical Research Council, Sarepta Therapeutics, Inc., and others.
Where is PepGen headquartered?: PepGen is headquartered in United States of America and employs approximately 65 people. It has been publicly traded since 2022.